Cargando…

Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma

BACKGROUND: Fumarate hydratase–deficient renal cell carcinoma (FH-RCC) is a rare highly aggressive subtype of kidney cancer for which the distinct genomic, transcriptomic, and evolutionary relationships between metastatic and primary lesions are still unclear. METHODS: In this study, whole-exome, RN...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jiayu, Sun, Guangxi, Pan, Xiuyi, Zhang, Mengni, Shen, Pengfei, Zhu, Sha, Zhao, Jinge, Zheng, Linmao, Zhao, Junjie, Chen, Yuntian, Yin, Xiaoxue, Chen, Junru, Hu, Xu, Zeng, Yuhao, Chen, Jianhui, Wang, Yongquan, Liu, Zhihong, Yao, Jin, Su, Minggang, Huang, Rui, Liao, Banghua, Wei, Qiang, Li, Xiang, Zhou, Qiao, Liu, Jiyan, Shen, Yali, Liu, Zhenhua, Chen, Ni, Zeng, Hao, Zhang, Xingming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152735/
https://www.ncbi.nlm.nih.gov/pubmed/37131267
http://dx.doi.org/10.1186/s13073-023-01182-7
_version_ 1785035798902472704
author Liang, Jiayu
Sun, Guangxi
Pan, Xiuyi
Zhang, Mengni
Shen, Pengfei
Zhu, Sha
Zhao, Jinge
Zheng, Linmao
Zhao, Junjie
Chen, Yuntian
Yin, Xiaoxue
Chen, Junru
Hu, Xu
Zeng, Yuhao
Chen, Jianhui
Wang, Yongquan
Liu, Zhihong
Yao, Jin
Su, Minggang
Huang, Rui
Liao, Banghua
Wei, Qiang
Li, Xiang
Zhou, Qiao
Liu, Jiyan
Shen, Yali
Liu, Zhenhua
Chen, Ni
Zeng, Hao
Zhang, Xingming
author_facet Liang, Jiayu
Sun, Guangxi
Pan, Xiuyi
Zhang, Mengni
Shen, Pengfei
Zhu, Sha
Zhao, Jinge
Zheng, Linmao
Zhao, Junjie
Chen, Yuntian
Yin, Xiaoxue
Chen, Junru
Hu, Xu
Zeng, Yuhao
Chen, Jianhui
Wang, Yongquan
Liu, Zhihong
Yao, Jin
Su, Minggang
Huang, Rui
Liao, Banghua
Wei, Qiang
Li, Xiang
Zhou, Qiao
Liu, Jiyan
Shen, Yali
Liu, Zhenhua
Chen, Ni
Zeng, Hao
Zhang, Xingming
author_sort Liang, Jiayu
collection PubMed
description BACKGROUND: Fumarate hydratase–deficient renal cell carcinoma (FH-RCC) is a rare highly aggressive subtype of kidney cancer for which the distinct genomic, transcriptomic, and evolutionary relationships between metastatic and primary lesions are still unclear. METHODS: In this study, whole-exome, RNA-seq, and DNA methylation sequencing were performed on primary-metastatic paired specimens from 19 FH-RCC cases, including 23 primary and 35 matched metastatic lesions. Phylogenetic and clonal evolutionary analyses were used to investigate the evolutionary characteristics of FH-RCC. Transcriptomic analyses, immunohistochemistry, and multiple immunofluorescence experiments were performed to identify the tumor microenvironmental features of metastatic lesions. RESULTS: Paired primary and metastatic lesions generally showed similar characteristics of tumor mutation burden, tumor neoantigen burden, microsatellite instability score, CNV burden, and genome instability index. Notably, we identified an FH-mutated founding MRCA (the most recent common ancestor) clone that dominated the early evolutionary trajectories in FH-RCC. Although both primary and metastatic lesions manifested high immunogenicity, metastatic lesions exhibited higher enrichment of T effector cells and immune-related chemokines, together with upregulation of PD-L1, TIGIT, and BTLA. In addition, we found that concurrent NF2 mutation may be associated with bone metastasis and upregulation of cell cycle signature in metastatic lesions. Furthermore, although in FH-RCC metastatic lesions in general shared similar CpG island methylator phenotype with primary lesions, we found metastatic lesions displaying hypomethylated chemokine and immune checkpoints related genomic loci. CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-023-01182-7.
format Online
Article
Text
id pubmed-10152735
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101527352023-05-03 Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma Liang, Jiayu Sun, Guangxi Pan, Xiuyi Zhang, Mengni Shen, Pengfei Zhu, Sha Zhao, Jinge Zheng, Linmao Zhao, Junjie Chen, Yuntian Yin, Xiaoxue Chen, Junru Hu, Xu Zeng, Yuhao Chen, Jianhui Wang, Yongquan Liu, Zhihong Yao, Jin Su, Minggang Huang, Rui Liao, Banghua Wei, Qiang Li, Xiang Zhou, Qiao Liu, Jiyan Shen, Yali Liu, Zhenhua Chen, Ni Zeng, Hao Zhang, Xingming Genome Med Research BACKGROUND: Fumarate hydratase–deficient renal cell carcinoma (FH-RCC) is a rare highly aggressive subtype of kidney cancer for which the distinct genomic, transcriptomic, and evolutionary relationships between metastatic and primary lesions are still unclear. METHODS: In this study, whole-exome, RNA-seq, and DNA methylation sequencing were performed on primary-metastatic paired specimens from 19 FH-RCC cases, including 23 primary and 35 matched metastatic lesions. Phylogenetic and clonal evolutionary analyses were used to investigate the evolutionary characteristics of FH-RCC. Transcriptomic analyses, immunohistochemistry, and multiple immunofluorescence experiments were performed to identify the tumor microenvironmental features of metastatic lesions. RESULTS: Paired primary and metastatic lesions generally showed similar characteristics of tumor mutation burden, tumor neoantigen burden, microsatellite instability score, CNV burden, and genome instability index. Notably, we identified an FH-mutated founding MRCA (the most recent common ancestor) clone that dominated the early evolutionary trajectories in FH-RCC. Although both primary and metastatic lesions manifested high immunogenicity, metastatic lesions exhibited higher enrichment of T effector cells and immune-related chemokines, together with upregulation of PD-L1, TIGIT, and BTLA. In addition, we found that concurrent NF2 mutation may be associated with bone metastasis and upregulation of cell cycle signature in metastatic lesions. Furthermore, although in FH-RCC metastatic lesions in general shared similar CpG island methylator phenotype with primary lesions, we found metastatic lesions displaying hypomethylated chemokine and immune checkpoints related genomic loci. CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-023-01182-7. BioMed Central 2023-05-02 /pmc/articles/PMC10152735/ /pubmed/37131267 http://dx.doi.org/10.1186/s13073-023-01182-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liang, Jiayu
Sun, Guangxi
Pan, Xiuyi
Zhang, Mengni
Shen, Pengfei
Zhu, Sha
Zhao, Jinge
Zheng, Linmao
Zhao, Junjie
Chen, Yuntian
Yin, Xiaoxue
Chen, Junru
Hu, Xu
Zeng, Yuhao
Chen, Jianhui
Wang, Yongquan
Liu, Zhihong
Yao, Jin
Su, Minggang
Huang, Rui
Liao, Banghua
Wei, Qiang
Li, Xiang
Zhou, Qiao
Liu, Jiyan
Shen, Yali
Liu, Zhenhua
Chen, Ni
Zeng, Hao
Zhang, Xingming
Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title_full Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title_fullStr Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title_full_unstemmed Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title_short Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
title_sort genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152735/
https://www.ncbi.nlm.nih.gov/pubmed/37131267
http://dx.doi.org/10.1186/s13073-023-01182-7
work_keys_str_mv AT liangjiayu genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT sunguangxi genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT panxiuyi genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhangmengni genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT shenpengfei genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhusha genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhaojinge genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhenglinmao genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhaojunjie genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT chenyuntian genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT yinxiaoxue genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT chenjunru genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT huxu genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zengyuhao genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT chenjianhui genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT wangyongquan genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT liuzhihong genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT yaojin genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT suminggang genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT huangrui genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT liaobanghua genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT weiqiang genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT lixiang genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhouqiao genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT liujiyan genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT shenyali genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT liuzhenhua genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT chenni genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zenghao genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma
AT zhangxingming genomicandtranscriptomicfeaturesbetweenprimaryandpairedmetastaticfumaratehydratasedeficientrenalcellcarcinoma